Prostatis Group’s Bristol-Myers Squibb BMY Stock Holding History

Prostatis Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$296K	Buy	+5,144	New	+$295K	0.07%	143

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Prostatis Group's BMY Position: Q2 2026 in Review

Prostatis Group opened a new position in Bristol-Myers Squibb (BMY) in Q2 2026: 5,144 shares worth $296K. The stake represents 0.07% of the portfolio and ranks #143 among its holdings.

2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Prostatis Group held 5,144 shares of Bristol-Myers Squibb worth $296K as of Q2 2026.
Bristol-Myers Squibb was a new Prostatis Group position in Q2 2026.
Bristol-Myers Squibb made up 0.07% of Prostatis Group's portfolio in Q2 2026, its #143 holding.
2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Prostatis Group's 13F filing for Q2 2026, filed 14 Aug 2026.